News Release
<< Back
Cumberland Pharmaceuticals Appoints New Senior Executive
Dr. Haeberle joins Cumberland from
Before
Haeberle also held several significant positions, such as associate director, clinical operations and regulatory affairs, in biotech startups and government. He has managed clinical development, regulatory activities and the overall program for an NIH government contract totaling greater than
"It's a pleasure to welcome Adam to our product development team," said
Haeberle earned his bachelor's degree in biology from
About
The Company's portfolio of
- Acetadote® (acetylcysteine) Injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) Injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;
- Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
- Vaprisol® (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
- Ethyol® (amifostine) Injection, for the reduction of xerostomia (dry mouth) in patients undergoing post-operative radiation treatment for head and neck cancer and the renal toxicity associated with the administration of cisplatin in patients with advanced ovarian cancer;
- Totect®(dexrazoxane hydrochloride) Injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy in case of extravasation (drug leakage from the bloodstream into the tissues).
Cumberland's pipeline of product candidates includes:
- Hepatoren® (ifetroban) Injection, a Phase II candidate for the treatment of critically ill patients suffering from liver and kidney failure associated with hepatorenal syndrome ("HRS");
- Boxaban®(ifetroban) Oral Capsules, a Phase II candidate for the treatment of asthma patients with aspirin-exacerbated respiratory disease ("AERD");
- Vasculan®(ifetroban) Oral Capsules, a Phase II candidate for the treatment of patients with the systemic sclerosis (SSc) form of autoimmune disease;
- Portaban®(ifetroban) Injection and Oral Capsules, a Phase II candidate for the treatment of patients with portal hypertension associated with liver disease;
- RediTrex™ (methotrexate) Injection, an approval submission candidate for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis.
For more information on Cumberland's approved products, including full prescribing instructions, please visit the individual product websites, links to which can be found on the Company's website www.cumberlandpharma.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-appoints-new-senior-executive-300695882.html
SOURCE
Investor Contact: Erin Smith, Corporate Relations, (615) 255-0068; Media Contact: Jeff Bradford, the Bradford Group, (615) 515-4880